CLLS Key Statistics, Chart & Performance
The current stock price of CLLS is 4.62 USD. In the past month the price increased by 44.83%. In the past year, price increased by 162.5%.
CLLS Latest News, Press Relases and Analysis
CLLS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.61 | 394.34B | ||
| AMGN | AMGEN INC | 14.69 | 172.98B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.36B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.46 | 112.15B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.62 | 73.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 843.18 | 56.81B | ||
| INSM | INSMED INC | N/A | 41.92B | ||
| NTRA | NATERA INC | N/A | 33.00B | ||
| BIIB | BIOGEN INC | 10.78 | 26.47B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.17 | 20.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.16B | ||
| INCY | INCYTE CORP | 15.06 | 18.98B |
Related stock screener links
About CLLS
Company Profile
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company is headquartered in Paris, Ile-De-France and currently employs 224 full-time employees. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.
Company Info
CELLECTIS - ADR
8, rue de la Croix Jarry
Paris ILE-DE-FRANCE 75013 FR
CEO: Andre Choulika
Employees: 219
Phone: 33181691600
CELLECTIS - ADR / CLLS FAQ
What does CELLECTIS - ADR do?
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company is headquartered in Paris, Ile-De-France and currently employs 224 full-time employees. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.
What is the current price of CLLS stock?
The current stock price of CLLS is 4.62 USD. The price decreased by -2.53% in the last trading session.
Does CELLECTIS - ADR pay dividends?
CLLS does not pay a dividend.
What is the ChartMill rating of CELLECTIS - ADR stock?
CLLS has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is CELLECTIS - ADR (CLLS) expected to grow?
The Revenue of CELLECTIS - ADR (CLLS) is expected to grow by 45.52% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the employee count for CLLS stock?
CELLECTIS - ADR (CLLS) currently has 219 employees.
CLLS Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CLLS. When comparing the yearly performance of all stocks, CLLS is one of the better performing stocks in the market, outperforming 97.42% of all stocks.
CLLS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CLLS. CLLS may be in some trouble as it scores bad on both profitability and health.
CLLS Financial Highlights
Over the last trailing twelve months CLLS reported a non-GAAP Earnings per Share(EPS) of -0.33. The EPS increased by 70.8% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.3% | ||
| ROE | -103.16% | ||
| Debt/Equity | 0.91 |
CLLS Forecast & Estimates
13 analysts have analysed CLLS and the average price target is 7.55 USD. This implies a price increase of 63.48% is expected in the next year compared to the current price of 4.62.
For the next year, analysts expect an EPS growth of -167.21% and a revenue growth 45.52% for CLLS